Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Purchase Now

Conference Agenda.

8:00AM - 9:20AM
Registration & Welcome Coffee
9:20AM - 9:30AM
Opening Address
9:30AM - 10:20AM
Keynote panel: A new pharma-stakeholder relationship. Form an aligned relationship to drive results
  • Collaborate with stakeholders to drive better patient outcomes and therapy access.
  • Understand how pharma can deliver value-based leadership and satisfy payers.
  • Align interests with stakeholders to ensure market access and secure reimbursement

Sandoz Seth Coombs Vice President, Oncology and Injectable Products Sandoz

CancerLinQ LLC Kevin Fitzpatrick CEO CancerLinQ LLC

Pfizer Bryon Wornson Vice President, Oncology Patient&Health Impact Pfizer

Moderator Cota Healthcare Ann Collins SVP of Strategy Cota Healthcare

10:20AM - 11:05AM
Co-Presentation: Tackling Cancer with Precision Data
  • Explore current approaches to clinical precision oncology
  • Understand what tools physicians will have access to, to be able to understand which molecular diagnostics they will need.
  • Work with large data sets generated in precision oncology and how to make it actionable for patient care

ARUP Laboratories Kendall Miller Clinical Product Manager - Oncology ARUP Laboratories

ARUP Laboratories Andrea Lorance Clinical Product Manager - Genetics ARUP Laboratories

11:05AM - 11:35AM
Networking Coffee Break
11:35AM - 12:05PM
Commercial-Clinical Integration – Essential for Sustaining Value
  • Learn about evolving payer models to balance access with affordability in light of rising cost burden of new oncology drugs
  • Understand the implications on biopharma planning for creating and sustaining value
  • Discover the importance of integrated market-back thinking in clinical development

INC Research Sriram Shankar Senior Consultant INC Strategy Consulting

12:05PM - 12:35PM
Case Study: Constructively engaging on value assessments

Merck Matthew Monberg Director, Outcomes Research Immuno-Oncology / PD-1 Merck

12:35PM - 1:05PM
Smarter use of data to evaluate performance
  • Drive standardization by identifying key sources of data needed to evaluate intrinsic product value
  • Capture therapy performance along the patient journey by using the right infrastructure
  • Learn how stakeholders can work together to share associated patient data collected, to generate new knowledge in cancer care and clinical insights

Pfizer James Harnett Senior Director, Analytical Sciences Lead Pfizer

1:05PM - 2:35PM
Exhibition & Networking Lunch Break
2:35PM - 3:05PM
Establish a future-proof value creation model
  • Capture the basic metrics needed to optimize value
  • Place the patient perspective at the heart of decision making
  • Track emerging evidence and uncontrolled variables to ensure you evolve as the landscape changes

GSK Amanda Bruno Senior Director, Value Evidence Leader, Cross Therapy Area GSK

3:05PM - 3:55PM
Panel: A deep dive into how Speciality Pharmacies and Pharmacy Benefit Managers are transforming the oncology landscape
  • Examining the role of Speciality Pharmacies in Oncology, and what it means for stakeholders.
  • Analyse how PBM’s are working with manufactures to improve overall value and care for patients.
  • Adopting best practices in working with Speciality Pharmacies and Pharmacy Benefit Managers.

Walgreens Anita Dopkosky Director, National Accounts Walgreens

NASP Burt Zweigenhaft Former President NASP

Moderator Health Policy Strategies, Inc. Jayson S. Slotnik Principal and founding member Health Policy Strategies, Inc.

3:55PM - 4:25PM
Networking Coffee Break
4:25PM - 4:55PM
Value-based contracting- Understand the payer perspective
  • Explore the evolution of conditional reimbursement of Cancer therapies
  • Understand the psychology of the payer: Do payers want to pay for healthcare innovation in Oncology?
  • What is the price of a cure?

NICE Omar Ali Visiting Lecturer, University of Portsmouth & Former Adviser, Adoption & Impact Panel NICE

4:55PM - 5:45PM
Panel: Scale & execute value-based contracts like a pro
  • A complete review of the contractual landscape.
  • A critical review of government legislation on price reporting and a way forward for reform
  • Hear how pharma and payers can mutually fund infrastructure to support Value-Based Contracts

Healthagen Aetna Van Crocker President, Outcomes team Healthagen Aetna

Pfizer Adrian Charbin Director, Global Payer Insights & Access: Immunoncology Pfizer

GlaxoSmithKline Amanda Bruno Senior Director, Value Evidence Leader, Cross Therapy Area GSK

Moderator: Takeda Oncology Ariella Evenzahav Former US Market Analytics Takeda Oncology

5:45PM - 7:00PM
Networking Drinks Reception
8:30AM - 9:25AM
Registration & Welcome Coffee
9:25AM - 9:40AM
Opening Address
9:40AM - 10:25AM
Panel: Patient Affordability. Bridge the gap between access and the patients pocket
  • Examine how you can address Patient Affordability and alleviate coverage inequality for oral therapies
  • Develop meaningful and progressive assistance programs which address a patients’ ability to afford medication.
  • Drive solutions that will relieve patient paying points as they move between different sites of care

American Cancer Society Sally Cowal Senior Vice President American Cancer Society

Eisai Inc. Bill Goodson Director, Market Access & Reimbursement Eisai Inc.

Good Days Clorinda Walley Executive Director Good Days

Moderator Patient Power Andrew Schorr Founder Patient Power

10:25AM - 10:55AM
A New approach to Patient Advocacy
  • Deliver better patient outcomes and enable patients to take ownership of their treatment
  • Tap into communities to cultivate long term relationships with patients and engage with them on an individual level
  • Understand why greater strategic pharma-pharma collaboration, not competition will drive innovation within cancer care and benefit patients

Cancer Support Community Dr. Joanne Buzaglo SVP, Research & Training Cancer Support Community

10:55AM - 11:25AM
Networking Coffee Break
11:25AM - 11:55AM
The new era of ‘survivorship’ – find value in extending and improving life
  • In-depth analysis of the value in pursuing the survivorship agenda: how will society pay for something which is priceless?
  • Understand the unique health challenges faced, as cancer care moves towards a chronic condition

CancerLinQ LLC Kevin Fitzpatrick CEO CancerLinQ, LLC

11:55AM - 12:40PM
Panel: Understanding the Oral Oncolytics Channel Opportunities and Challenges
  • Explore how oral oncology care is driven today across community oncology and the impact to market access
  • Uncover the PBM and payor ecosystems, industry trends and challenges
  • Advocate for greater transparency in the marketplace for optimal patient care

Lancaster Cancer Centre Bob Orzechowski CEO Lancaster Cancer Centre

National Community Oncology Dispensing Association Michael Reff Founder National Community Oncology Dispensing Association

Oncology Consultants Yen Nguyen Director of Pharmacy Oncology Consultants

12:40PM - 1:40PM
Networking Lunch Break
1:40PM - 2:25PM
Panel: Set the standard by defining your outputs and creating your own value framework
  • Go beyond those standards developed by the NCCN, ASCO, ICER, ACC-AHA, and NPC
  • Find and close the gaps in these existing value assessment frameworks
  • Control the value conversation and become influential in framework decisions

EMD Serono Julie Locklear VP & Head – Health economics & Outcomes research EMD Serono

Pfizer Bryon Wornson Vice President, Oncology Patient&Health Impact Pfizer

Takeda Oncology Ariella Evenzahav Former US Market Analytics Takeda Oncology

Moderator NICE Omar Ali Visiting Lecturer, University of Portsmouth & Former Adviser, Adoption & Impact Panel NICE

2:25PM - 2:55PM
The new era in Cancer diagnostics
  • Absorb and gain insights from the large data sets generated in precision oncology
  • Understand how technology platforms can power advanced analytics
  • Empower patients to improve health outcomes & health care management

Quest Diagnostics Mridula Iyer Director Companion Diagnostics Quest Diagnostics

2:55PM - 3:25PM
The Promise of Precision Medicine- how will it make a real difference?
  • An examination of the emerging precision therapeutic options and how value is being determined
  • Optimize the commercialization strategy of targeted therapies and immuno therapies
  • Understand how data can provide insights on what direction to take from therapeutic and commercial standpoint

Foundation Medicine Jerry Conway Vice President of Reimbursement & Payer Strategy Foundation Medicine

3:25PM
End of Conference
8:00AM - 9:20AM
Registration & Welcome Coffee
9:20AM - 9:30AM
Opening Address
9:30AM - 10:20AM
Keynote panel: A new pharma-stakeholder relationship. Form an aligned relationship to drive results
  • Collaborate with stakeholders to drive better patient outcomes and therapy access.
  • Understand how pharma can deliver value-based leadership and satisfy payers.
  • Align interests with stakeholders to ensure market access and secure reimbursement

Sandoz Seth Coombs Vice President, Oncology and Injectable Products Sandoz

CancerLinQ LLC Kevin Fitzpatrick CEO CancerLinQ LLC

Pfizer Bryon Wornson Vice President, Oncology Patient&Health Impact Pfizer

Moderator Cota Healthcare Ann Collins SVP of Strategy Cota Healthcare

10:20AM - 11:05AM
Co-Presentation: Tackling Cancer with Precision Data
  • Explore current approaches to clinical precision oncology
  • Understand what tools physicians will have access to, to be able to understand which molecular diagnostics they will need.
  • Work with large data sets generated in precision oncology and how to make it actionable for patient care

ARUP Laboratories Kendall Miller Clinical Product Manager - Oncology ARUP Laboratories

ARUP Laboratories Andrea Lorance Clinical Product Manager - Genetics ARUP Laboratories

11:05AM - 11:35AM
Networking Coffee Break
11:35AM - 12:05PM
Commercial-Clinical Integration – Essential for Sustaining Value
  • Learn about evolving payer models to balance access with affordability in light of rising cost burden of new oncology drugs
  • Understand the implications on biopharma planning for creating and sustaining value
  • Discover the importance of integrated market-back thinking in clinical development

INC Research Sriram Shankar Senior Consultant INC Strategy Consulting

12:05PM - 12:35PM
Case Study: Constructively engaging on value assessments

Merck Matthew Monberg Director, Outcomes Research Immuno-Oncology / PD-1 Merck

12:35PM - 1:05PM
Smarter use of data to evaluate performance
  • Drive standardization by identifying key sources of data needed to evaluate intrinsic product value
  • Capture therapy performance along the patient journey by using the right infrastructure
  • Learn how stakeholders can work together to share associated patient data collected, to generate new knowledge in cancer care and clinical insights

Pfizer James Harnett Senior Director, Analytical Sciences Lead Pfizer

1:05PM - 2:35PM
Exhibition & Networking Lunch Break
2:35PM - 3:05PM
Establish a future-proof value creation model
  • Capture the basic metrics needed to optimize value
  • Place the patient perspective at the heart of decision making
  • Track emerging evidence and uncontrolled variables to ensure you evolve as the landscape changes

GSK Amanda Bruno Senior Director, Value Evidence Leader, Cross Therapy Area GSK

3:05PM - 3:55PM
Panel: A deep dive into how Speciality Pharmacies and Pharmacy Benefit Managers are transforming the oncology landscape
  • Examining the role of Speciality Pharmacies in Oncology, and what it means for stakeholders.
  • Analyse how PBM’s are working with manufactures to improve overall value and care for patients.
  • Adopting best practices in working with Speciality Pharmacies and Pharmacy Benefit Managers.

Walgreens Anita Dopkosky Director, National Accounts Walgreens

NASP Burt Zweigenhaft Former President NASP

Moderator Health Policy Strategies, Inc. Jayson S. Slotnik Principal and founding member Health Policy Strategies, Inc.

3:55PM - 4:25PM
Networking Coffee Break
4:25PM - 4:55PM
Value-based contracting- Understand the payer perspective
  • Explore the evolution of conditional reimbursement of Cancer therapies
  • Understand the psychology of the payer: Do payers want to pay for healthcare innovation in Oncology?
  • What is the price of a cure?

NICE Omar Ali Visiting Lecturer, University of Portsmouth & Former Adviser, Adoption & Impact Panel NICE

4:55PM - 5:45PM
Panel: Scale & execute value-based contracts like a pro
  • A complete review of the contractual landscape.
  • A critical review of government legislation on price reporting and a way forward for reform
  • Hear how pharma and payers can mutually fund infrastructure to support Value-Based Contracts

Healthagen Aetna Van Crocker President, Outcomes team Healthagen Aetna

Pfizer Adrian Charbin Director, Global Payer Insights & Access: Immunoncology Pfizer

GlaxoSmithKline Amanda Bruno Senior Director, Value Evidence Leader, Cross Therapy Area GSK

Moderator: Takeda Oncology Ariella Evenzahav Former US Market Analytics Takeda Oncology

5:45PM - 7:00PM
Networking Drinks Reception

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription

8:30AM - 9:25AM
Registration & Welcome Coffee
9:25AM - 9:40AM
Opening Address
9:40AM - 10:25AM
Panel: Patient Affordability. Bridge the gap between access and the patients pocket
  • Examine how you can address Patient Affordability and alleviate coverage inequality for oral therapies
  • Develop meaningful and progressive assistance programs which address a patients’ ability to afford medication.
  • Drive solutions that will relieve patient paying points as they move between different sites of care

American Cancer Society Sally Cowal Senior Vice President American Cancer Society

Eisai Inc. Bill Goodson Director, Market Access & Reimbursement Eisai Inc.

Good Days Clorinda Walley Executive Director Good Days

Moderator Patient Power Andrew Schorr Founder Patient Power

10:25AM - 10:55AM
A New approach to Patient Advocacy
  • Deliver better patient outcomes and enable patients to take ownership of their treatment
  • Tap into communities to cultivate long term relationships with patients and engage with them on an individual level
  • Understand why greater strategic pharma-pharma collaboration, not competition will drive innovation within cancer care and benefit patients

Cancer Support Community Dr. Joanne Buzaglo SVP, Research & Training Cancer Support Community

10:55AM - 11:25AM
Networking Coffee Break
11:25AM - 11:55AM
The new era of ‘survivorship’ – find value in extending and improving life
  • In-depth analysis of the value in pursuing the survivorship agenda: how will society pay for something which is priceless?
  • Understand the unique health challenges faced, as cancer care moves towards a chronic condition

CancerLinQ LLC Kevin Fitzpatrick CEO CancerLinQ, LLC

11:55AM - 12:40PM
Panel: Understanding the Oral Oncolytics Channel Opportunities and Challenges
  • Explore how oral oncology care is driven today across community oncology and the impact to market access
  • Uncover the PBM and payor ecosystems, industry trends and challenges
  • Advocate for greater transparency in the marketplace for optimal patient care

Lancaster Cancer Centre Bob Orzechowski CEO Lancaster Cancer Centre

National Community Oncology Dispensing Association Michael Reff Founder National Community Oncology Dispensing Association

Oncology Consultants Yen Nguyen Director of Pharmacy Oncology Consultants

12:40PM - 1:40PM
Networking Lunch Break
1:40PM - 2:25PM
Panel: Set the standard by defining your outputs and creating your own value framework
  • Go beyond those standards developed by the NCCN, ASCO, ICER, ACC-AHA, and NPC
  • Find and close the gaps in these existing value assessment frameworks
  • Control the value conversation and become influential in framework decisions

EMD Serono Julie Locklear VP & Head – Health economics & Outcomes research EMD Serono

Pfizer Bryon Wornson Vice President, Oncology Patient&Health Impact Pfizer

Takeda Oncology Ariella Evenzahav Former US Market Analytics Takeda Oncology

Moderator NICE Omar Ali Visiting Lecturer, University of Portsmouth & Former Adviser, Adoption & Impact Panel NICE

2:25PM - 2:55PM
The new era in Cancer diagnostics
  • Absorb and gain insights from the large data sets generated in precision oncology
  • Understand how technology platforms can power advanced analytics
  • Empower patients to improve health outcomes & health care management

Quest Diagnostics Mridula Iyer Director Companion Diagnostics Quest Diagnostics

2:55PM - 3:25PM
The Promise of Precision Medicine- how will it make a real difference?
  • An examination of the emerging precision therapeutic options and how value is being determined
  • Optimize the commercialization strategy of targeted therapies and immuno therapies
  • Understand how data can provide insights on what direction to take from therapeutic and commercial standpoint

Foundation Medicine Jerry Conway Vice President of Reimbursement & Payer Strategy Foundation Medicine

3:25PM
End of Conference

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription